Sector · close of Oct 30, 2026
Health Care Stocks
501 US-listed health care companies above our tradable floor ($5 and $1 million a day), largest first, with each one's stage, price and valuation after the close.
501
companies
191 (38%)
in a Stage 2 uptrend
+15.9%
3-month return, weighted by size
30 · 117 · 137
in Stage 1 · 3 · 4
Only the Stage 2 ones →Filter them in the screener →Sector rotation →
Industries in Health Care
| Industry | Companies | In Stage 2 | 3-month return |
|---|---|---|---|
| Biotechnology | 238 | 60 | +32.0% |
| Medical Devices | 70 | 24 | +0.5% |
| Drug Manufacturers - Specialty & Generic | 38 | 16 | +9.5% |
| Medical Care Facilities | 35 | 18 | +10.6% |
| Diagnostics & Research | 34 | 27 | +22.0% |
| Medical Instruments & Supplies | 33 | 14 | +6.6% |
| Health Information Services | 23 | 14 | +41.7% |
| Drug Manufacturers - General | 16 | 9 | +16.8% |
| Healthcare Plans | 10 | 6 | +0.1% |
| Medical Distribution | 4 | 3 | +13.0% |
The 100 largest health care stocks
| Stock | Industry | Stage | Close | Day | 3 months | From high | RS | P/E | Yield | Market cap |
|---|---|---|---|---|---|---|---|---|---|---|
| LLYEli Lilly | Drug Manufacturers - General | Stage 2, wk 2 | $1,417.54 | +3.2% | +26.6% | 0.0% | 92 | 43.9 | 0.54% | $1.26T |
| JNJJohnson & Johnson | Drug Manufacturers - General | Stage 2, wk 17 | $273.20 | -0.7% | +7.9% | -1.9% | 86 | 40.6 | 2.08% | $658B |
| ABBVAbbVie | Drug Manufacturers - General | Stage 2, wk 17 | $294.89 | +1.4% | +21.1% | 0.0% | 79 | 80.6 | 2.43% | $521B |
| MRKMerck | Drug Manufacturers - General | Stage 2, wk 18 | $149.52 | +2.2% | +17.7% | -3.9% | 92 | 116.9 | 2.27% | $369B |
| UNHUnitedHealth Group | Healthcare Plans | Stage 3, wk 8 | $406.97 | -1.0% | -1.4% | -6.2% | 67 | 27.3 | 2.23% | $365B |
| NVSNovartis | Drug Manufacturers - General | Stage 4, wk 4 | $160.79 | -0.2% | +4.6% | -1.7% | 79 | 23.6 | 3.08% | $304B |
| AZNAstraZeneca | Drug Manufacturers - General | Stage 1, wk 1 | $186.65 | +7.0% | +18.2% | -10.5% | 65 | 25.8 | 1.90% | $289B |
| TMOThermo Fisher Scientific | Diagnostics & Research | Stage 2, wk 11 | $697.00 | -1.7% | +21.5% | -1.7% | 73 | 35.7 | 0.27% | $258B |
| AMGNAmgen | Drug Manufacturers - General | Stage 2, wk 17 | $466.01 | +1.1% | +23.7% | 0.0% | 90 | 27.9 | 2.30% | $252B |
| GILDGilead Sciences | Drug Manufacturers - General | Stage 2, wk 10 | $170.68 | +3.1% | +30.9% | 0.0% | 85 | — | 2.14% | $212B |
| ABTAbbott Laboratories | Medical Devices | Stage 3, wk 2 | $106.20 | +1.6% | -0.2% | -16.7% | 44 | 38.2 | 2.51% | $184B |
| NVONovo Nordisk | Drug Manufacturers - General | Stage 4, wk 5 | $40.00 | +2.2% | -14.0% | -34.4% | 40 | 9.6 | 4.60% | $176B |
| PFEPfizer | Drug Manufacturers - General | Stage 2, wk 10 | $30.52 | +1.9% | +21.9% | 0.0% | 78 | 40.0 | 5.76% | $174B |
| DHRDanaher | Diagnostics & Research | Stage 2, wk 8 | $232.23 | -2.0% | +17.8% | -3.5% | 61 | 38.1 | 0.68% | $163B |
| ISRGIntuitive Surgical | Medical Instruments & Supplies | Stage 1, wk 4 | $432.01 | -3.7% | +15.1% | -27.1% | 39 | 53.7 | — | $153B |
| VRTXVertex Pharmaceuticals | Biotechnology | Stage 2, wk 18 | $558.88 | +3.5% | +18.7% | 0.0% | 78 | 31.0 | — | $142B |
| BMYBristol-Myers Squibb | Drug Manufacturers - General | Stage 3, wk 3 | $62.48 | +1.8% | -3.6% | -7.3% | 87 | 13.9 | 4.12% | $128B |
| MDTMedtronic | Medical Devices | Stage 2, wk 7 | $96.54 | -0.6% | +12.3% | -5.3% | 60 | 23.7 | 3.10% | $123B |
| MCKMcKesson | Medical Distribution | Stage 2, wk 9 | $994.58 | +1.4% | +20.4% | -3.5% | 72 | 27.1 | 0.37% | $116B |
| CVSCVS Health | Healthcare Plans | Stage 3, wk 9 | $90.25 | -0.1% | -13.7% | -17.3% | 65 | 24.9 | 2.85% | $115B |
| SYKStryker | Medical Devices | Stage 4, wk 7 | $291.86 | -6.4% | -14.2% | -24.0% | 39 | 31.8 | 1.18% | $111B |
| SNYSanofi | Drug Manufacturers - General | Stage 4, wk 5 | $44.34 | +2.8% | +3.2% | -10.6% | 48 | 22.1 | 5.90% | $106B |
| GSKGSK | Drug Manufacturers - General | Stage 4, wk 8 | $49.51 | +1.7% | -3.0% | -16.9% | 62 | 16.2 | 3.63% | $99.2B |
| HCAHCA Healthcare | Medical Care Facilities | Stage 1, wk 11 | $473.19 | -1.0% | +16.6% | -12.7% | 55 | 15.7 | 0.68% | $98.8B |
| REGNRegeneron Pharmaceuticals | Biotechnology | Stage 2, wk 9 | $927.89 | +13.3% | +22.4% | 0.0% | 83 | 20.3 | 0.47% | $96.0B |
| ELVElevance Health | Healthcare Plans | Stage 2, wk 7 | $420.07 | -0.5% | +10.2% | -5.7% | 74 | 18.9 | 1.58% | $91.1B |
| MRNAModerna | Biotechnology | Stage 2, wk 18 | $221.72 | -0.5% | +302.1% | -9.8% | 99 | — | — | $88.5B |
| CICigna Group | Healthcare Plans | Stage 2, wk 2 | $298.23 | -0.1% | +6.3% | -5.6% | 55 | 13.1 | 2.05% | $78.8B |
| TAKTakeda Pharmaceutical | Drug Manufacturers - Specialty & Generic | Stage 2, wk 12 | $20.91 | +4.5% | +24.2% | 0.0% | 86 | — | 3.09% | $66.8B |
| CORCencora | Medical Distribution | Stage 2, wk 5 | $330.84 | +0.1% | +7.5% | -11.2% | 54 | 25.1 | 0.71% | $63.1B |
| BSXBoston Scientific | Medical Devices | Stage 4, wk 4 | $41.98 | -1.7% | -13.3% | -60.0% | 20 | 18.6 | — | $60.8B |
| NTRANatera | Diagnostics & Research | Stage 2, wk 21 | $414.30 | -5.0% | +53.2% | -5.0% | 96 | — | — | $59.7B |
| CAHCardinal Health | Medical Distribution | Stage 2, wk 2 | $250.48 | -0.2% | +6.6% | -2.9% | 87 | 35.4 | 0.80% | $58.0B |
| ARGXargenx | Biotechnology | Stage 3, wk 1 | $892.87 | -0.6% | +7.5% | -15.7% | 60 | 33.4 | — | $56.1B |
| BDXBecton, Dickinson | Medical Instruments & Supplies | Stage 2, wk 12 | $197.88 | -0.2% | +16.9% | -1.3% | 82 | 46.4 | 2.16% | $53.9B |
| EWEdwards Lifesciences | Medical Devices | Stage 3, wk 6 | $92.01 | -2.6% | +3.6% | -3.3% | 62 | 53.6 | — | $53.0B |
| VEEVVeeva Systems | Health Information Services | Stage 2, wk 10 | $312.96 | +0.8% | +51.7% | -3.1% | 61 | 52.9 | — | $50.7B |
| HUMHumana | Healthcare Plans | Stage 2, wk 3 | $414.50 | -0.7% | +10.7% | -4.4% | 83 | 39.8 | 0.83% | $49.8B |
| AAgilent Technologies | Diagnostics & Research | Stage 2, wk 14 | $174.87 | -3.5% | +25.3% | -3.6% | 71 | 34.3 | 0.57% | $49.3B |
| TEVATeva Pharmaceutical Industries | Drug Manufacturers - Specialty & Generic | Stage 2, wk 11 | $42.09 | +1.5% | +22.1% | 0.0% | 95 | 67.0 | — | $49.1B |
| WATWaters | Diagnostics & Research | Stage 2, wk 18 | $462.72 | -3.6% | +23.5% | -3.6% | 79 | 115.3 | — | $45.4B |
| IQVIQVIA Holdings | Diagnostics & Research | Stage 2, wk 13 | $267.33 | -2.8% | +14.6% | -4.3% | 71 | 34.6 | — | $44.1B |
| IDXXIDEXX Laboratories | Diagnostics & Research | Stage 4, wk 8 | $551.21 | -4.3% | -2.9% | -28.1% | 45 | 39.8 | — | $43.4B |
| MDLNMedline | Medical Instruments & Supplies | Stage 4, wk 4 | $32.12 | +0.4% | -20.6% | — | — | 87.2 | — | $43.2B |
| ONCBeOne Medicines | Biotechnology | Stage 2, wk 10 | $370.33 | -0.3% | +18.0% | -4.8% | 67 | 68.4 | — | $42.1B |
| RVMDRevolution Medicines | Biotechnology | Stage 3, wk 1 | $191.31 | +0.5% | +4.9% | -13.5% | 98 | — | — | $41.0B |
| RPRXRoyalty Pharma | Biotechnology | Stage 2, wk 50 | $67.18 | +1.9% | +18.0% | 0.0% | 93 | 33.9 | 1.51% | $38.8B |
| HLNHaleon | Drug Manufacturers - Specialty & Generic | Stage 4, wk 5 | $8.66 | +1.1% | -11.1% | -21.6% | 52 | 21.2 | 1.98% | $38.1B |
| BIIBBiogen | Drug Manufacturers - General | Stage 2, wk 22 | $253.62 | +1.6% | +25.7% | -0.1% | 91 | 45.1 | — | $37.5B |
| ILMNIllumina | Diagnostics & Research | Stage 2, wk 25 | $235.99 | -18.6% | +19.1% | -19.6% | 97 | 50.3 | — | $35.7B |
| GMABGenmab | Biotechnology | Stage 2, wk 10 | $57.06 | +1.0% | +99.0% | -0.4% | 95 | 31.5 | — | $35.1B |
| GEHCGE HealthCare Technologies | Medical Devices | Stage 1, wk 13 | $76.57 | +0.2% | +9.8% | -13.0% | 53 | 16.4 | 0.23% | $34.6B |
| ALCAlcon | Medical Instruments & Supplies | Stage 4, wk 5 | $71.45 | +0.4% | +1.8% | -17.6% | 52 | 53.5 | 0.53% | $34.5B |
| CNCCentene | Healthcare Plans | Stage 2, wk 2 | $68.45 | -0.2% | +7.4% | -3.9% | 93 | — | — | $33.9B |
| MTDMettler-Toledo International | Diagnostics & Research | Stage 2, wk 10 | $1,674.81 | -2.5% | +15.9% | -2.5% | 69 | 38.0 | — | $33.6B |
| ZTSZoetis | Drug Manufacturers - Specialty & Generic | Stage 1, wk 1 | $79.72 | +1.2% | +3.4% | -43.9% | 27 | 13.5 | 2.66% | $32.9B |
| RMDResMed | Medical Instruments & Supplies | Stage 2, wk 4 | $229.94 | -9.1% | +7.2% | -16.0% | 47 | 24.3 | 1.07% | $32.3B |
| DXCMDexCom | Medical Devices | Stage 3, wk 1 | $82.29 | +3.0% | -5.7% | -10.9% | 70 | 31.1 | — | $30.7B |
| LHLabcorp Holdings | Diagnostics & Research | Stage 2, wk 15 | $361.39 | -1.8% | +17.8% | -1.8% | 84 | 27.3 | 0.89% | $29.3B |
| WSTWest Pharmaceutical Services | Medical Instruments & Supplies | Stage 2, wk 25 | $412.62 | -1.0% | +18.6% | -1.0% | 84 | 50.5 | 0.26% | $28.7B |
| DGXQuest Diagnostics | Diagnostics & Research | Stage 2, wk 18 | $251.82 | -0.4% | +9.0% | -0.4% | 84 | 25.9 | 1.44% | $27.8B |
| ROIVRoivant Sciences | Biotechnology | Stage 2, wk 65 | $36.91 | -1.6% | +10.8% | -11.7% | 94 | — | — | $26.7B |
| PHGKoninklijke Philips N.V. NY Registry Shares | Medical Devices | Stage 4, wk 7 | $26.92 | -0.7% | +2.6% | -15.0% | 55 | 20.1 | 3.86% | $26.3B |
| UTHRUnited Therapeutics | Drug Manufacturers - Specialty & Generic | Stage 1, wk 2 | $598.72 | +0.9% | +16.0% | 0.0% | 77 | 20.9 | — | $25.7B |
| INSMInsmed | Biotechnology | Stage 4, wk 2 | $112.58 | +0.9% | +14.4% | -46.7% | 32 | — | — | $24.7B |
| INCYIncyte | Biotechnology | Stage 3, wk 2 | $120.39 | +3.1% | +1.7% | -7.3% | 78 | 14.9 | — | $24.5B |
| GHGuardant Health | Diagnostics & Research | Stage 2, wk 23 | $178.80 | -3.5% | +12.6% | -4.5% | 97 | — | — | $24.0B |
| BNTXBioNTech | Biotechnology | Stage 3, wk 1 | $88.17 | -1.1% | -4.4% | -26.1% | 43 | — | — | $22.1B |
| STESTERIS plc (Ireland) | Medical Devices | Stage 4, wk 4 | $227.12 | -2.2% | -2.1% | -14.7% | 51 | 28.4 | 1.16% | $22.1B |
| ALNYAlnylam Pharmaceuticals | Biotechnology | Stage 4, wk 37 | $165.00 | -5.2% | -25.1% | -65.1% | 17 | 38.3 | — | $22.1B |
| VTRSViatris | Drug Manufacturers - Specialty & Generic | Stage 2, wk 57 | $19.04 | -0.9% | +8.8% | -0.9% | 94 | — | 2.60% | $21.9B |
| THCTenet Healthcare | Medical Care Facilities | Stage 2, wk 12 | $273.25 | +1.0% | +9.3% | -2.7% | 76 | 10.5 | — | $21.7B |
| MEDPMedpace Holdings | Diagnostics & Research | Stage 2, wk 12 | $652.01 | -3.8% | +13.7% | -5.9% | 62 | 36.3 | — | $18.2B |
| ZBHZimmer Biomet Holdings | Medical Devices | Stage 3, wk 3 | $94.52 | -3.0% | -2.3% | -7.4% | 50 | 24.0 | 1.01% | $18.0B |
| RVTYRevvity | Diagnostics & Research | Stage 2, wk 19 | $157.00 | -5.3% | +36.3% | -5.3% | 90 | 75.3 | 0.18% | $17.5B |
| CRLCharles River Laboratories International | Diagnostics & Research | Stage 2, wk 17 | $359.41 | -4.4% | +55.7% | -4.4% | 95 | — | — | $17.3B |
| EXELExelixis | Biotechnology | Stage 2, wk 27 | $69.39 | +4.8% | +26.0% | 0.0% | 92 | 20.6 | — | $16.9B |
| ASNDAscendis Pharma | Biotechnology | Stage 3, wk 6 | $251.27 | -0.7% | +3.2% | -9.3% | 71 | 18.6 | — | $16.5B |
| ICLRICON | Diagnostics & Research | Stage 2, wk 14 | $211.36 | -1.9% | +33.4% | -1.9% | 74 | 195.2 | — | $15.8B |
| HALOHalozyme Therapeutics | Biotechnology | Stage 2, wk 17 | $130.91 | -0.2% | +59.1% | -0.2% | 95 | 36.4 | — | $14.9B |
| NBIXNeurocrine Biosciences | Drug Manufacturers - Specialty & Generic | Stage 4, wk 1 | $146.10 | -0.2% | -12.1% | -21.2% | 58 | 21.0 | — | $14.9B |
| BBIOBridgeBio Pharma | Biotechnology | Stage 4, wk 3 | $74.95 | +6.0% | -6.3% | -16.9% | 63 | — | — | $14.6B |
| GKOSGlaukos | Medical Devices | Stage 2, wk 26 | $237.60 | -2.0% | +39.1% | -2.0% | 98 | — | — | $14.1B |
| JAZZJazz Pharmaceuticals | Biotechnology | Stage 3, wk 5 | $215.98 | +3.9% | -14.2% | -17.4% | 88 | 14.7 | — | $14.0B |
| SOLVSolventum | Medical Instruments & Supplies | Stage 2, wk 18 | $81.33 | -2.7% | -7.7% | -12.0% | 66 | 10.7 | — | $13.8B |
| EHCEncompass Health | Medical Care Facilities | Stage 2, wk 12 | $135.90 | +3.4% | +21.0% | 0.0% | 60 | 21.1 | 0.70% | $13.4B |
| BTSGBrightSpring Health Services | Health Information Services | Stage 3, wk 9 | $66.89 | +11.1% | +10.6% | -8.3% | 94 | 53.9 | — | $13.3B |
| TEMTempus AI | Health Information Services | Stage 2, wk 7 | $72.22 | -7.2% | +56.8% | -19.6% | 40 | — | — | $13.2B |
| SMMTSummit Therapeutics | Biotechnology | Stage 1, wk 8 | $16.03 | -1.0% | +22.9% | -39.2% | 43 | — | — | $12.8B |
| PENPenumbra | Medical Devices | Stage 1, wk 9 | $318.95 | -0.9% | -1.3% | -11.3% | 80 | 79.8 | — | $12.6B |
| SNNSmith & Nephew SNATS | Medical Devices | Stage 4, wk 10 | $29.70 | -2.3% | -6.5% | -17.6% | 43 | 21.0 | 2.72% | $12.4B |
| FMSFresenius Medical Care | Medical Care Facilities | Stage 4, wk 1 | $22.47 | -2.9% | -11.0% | -12.9% | 44 | 11.5 | 4.04% | $12.0B |
| BAXBaxter International | Medical Instruments & Supplies | Stage 3, wk 2 | $23.00 | -2.1% | -18.1% | -18.8% | 56 | — | 0.16% | $11.9B |
| RDYDr. Reddy's Laboratories | Drug Manufacturers - Specialty & Generic | Stage 1, wk 3 | $14.17 | +0.4% | +17.4% | -7.2% | 58 | 30.1 | 0.63% | $11.8B |
| DVADaVita | Medical Care Facilities | Stage 3, wk 10 | $187.50 | -3.0% | -19.8% | -22.2% | 85 | 15.7 | — | $11.8B |
| ELANElanco Animal Health | Drug Manufacturers - Specialty & Generic | Stage 4, wk 5 | $23.06 | -0.8% | -10.3% | -14.1% | 55 | — | — | $11.5B |
| TECHBio-Techne | Biotechnology | Stage 2, wk 14 | $72.66 | -0.1% | +0.8% | -0.1% | 67 | 62.6 | 0.44% | $11.4B |
| BMRNBioMarin Pharmaceutical | Biotechnology | Stage 3, wk 3 | $58.51 | +1.8% | -2.5% | -16.7% | 63 | 153.1 | — | $11.3B |
| COOCooper Companies | Medical Instruments & Supplies | Stage 4, wk 7 | $59.55 | -1.3% | -19.8% | -29.4% | 43 | 21.2 | — | $11.3B |
| RGENRepligen | Medical Instruments & Supplies | Stage 2, wk 12 | $176.94 | -6.2% | +20.3% | -9.1% | 68 | 244.8 | — | $11.3B |
And 401 more. See all of them in the screener →
Health Care Stocks: quick answers
How many health care stocks are in an uptrend?
As of Oct 30, 2026, 191 of the 501 US-listed health care stocks we cover are in Stage 2, the uptrend phase, including Eli Lilly (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), Merck (MRK) and Thermo Fisher Scientific (TMO).
What is the largest health care stock?
Eli Lilly (LLY), with a market value of $1.26T. It closed at $1,417.54 on Oct 30, 2026, in Stage 2.
Which health care stocks are near their 52-week high?
As of Oct 30, 2026, 6 are within 5% of a 52-week high: Eli Lilly (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), Merck (MRK), Novartis (NVS) and Thermo Fisher Scientific (TMO).
End-of-day data for common stocks and ADRs on the NYSE, Nasdaq and NYSE American, computed after each US close and dated to the trading session.